Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2 by Peach, Chloe et al.
 International Journal of 
Molecular Sciences
Review
Molecular Pharmacology of VEGF-A Isoforms:
Binding and Signalling at VEGFR2
Chloe J. Peach 1,2, Viviane W. Mignone 1,2,3, Maria Augusta Arruda 1,2,3 ID , Diana C. Alcobia 1,2,
Stephen J. Hill 1,2, Laura E. Kilpatrick 1,2,* and Jeanette Woolard 1,2,*
1 Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre,
University of Nottingham, Nottingham NG7 2UH, UK; chloe.peach@nottingham.ac.uk (C.J.P.);
viviane.mignone@nottingham.ac.uk (V.W.M.); maria.arruda@nottingham.ac.uk (M.A.A.);
mbxdc1@nottingham.ac.uk (D.C.A.); steve.hill@nottingham.ac.uk (S.J.H.)
2 Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham
and University of Nottingham, Midlands NG7 2UH, UK
3 CAPES-University of Nottingham Programme in Drug Discovery, Queen’s Medical Centre,
University of Nottingham, Nottingham NG7 2UH, UK
* Correspondence: laura.kilpatrick@nottingham.ac.uk (L.E.K.); jeanette.woolard@nottingham.ac.uk (J.W.);
Tel.: +44-115-8230080 (L.E.K.); +44-115-8231481(J.W.)
Received: 28 March 2018; Accepted: 16 April 2018; Published: 23 April 2018


Abstract: Vascular endothelial growth factor-A (VEGF-A) is a key mediator of angiogenesis, signalling via
the class IV tyrosine kinase receptor family of VEGF Receptors (VEGFRs). Although VEGF-A ligands bind
to both VEGFR1 and VEGFR2, they primarily signal via VEGFR2 leading to endothelial cell proliferation,
survival, migration and vascular permeability. Distinct VEGF-A isoforms result from alternative splicing
of the Vegfa gene at exon 8, resulting in VEGFxxxa or VEGFxxxb isoforms. Alternative splicing events
at exons 5–7, in addition to recently identified posttranslational read-through events, produce VEGF-A
isoforms that differ in their bioavailability and interaction with the co-receptor Neuropilin-1. This review
explores the molecular pharmacology of VEGF-A isoforms at VEGFR2 in respect to ligand binding and
downstream signalling. To understand how VEGF-A isoforms have distinct signalling despite similar
affinities for VEGFR2, this review re-evaluates the typical classification of these isoforms relative to the
prototypical, “pro-angiogenic” VEGF165a. We also examine the molecular mechanisms underpinning the
regulation of VEGF-A isoform signalling and the importance of interactions with other membrane and
extracellular matrix proteins. As approved therapeutics targeting the VEGF-A/VEGFR signalling axis
largely lack long-term efficacy, understanding these isoform-specific mechanisms could aid future drug
discovery efforts targeting VEGF receptor pharmacology.
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1. Introduction
Angiogenesis is the formation of new blood vessels by the sprouting of endothelial cells
from pre-existing vasculature [1]. While vasculogenesis (formation of angioblast-derived blood
vessels) occurs mainly during embryonic development, angiogenesis takes place throughout adult
life [2,3], playing a vital role in physiological events such as wound repair [4], the oestrous cycle
and placentation [5]. In addition to its importance in normal physiology, angiogenesis is also a key
feature associated not only with cancer [6], but also with several pathological conditions including
age-related macular degeneration [7], rheumatoid arthritis [8], psoriasis [9], diabetes-induced ocular
neovascularisation [10], inflammatory diseases [11], ischaemia/reperfusion injury [12], infantile
haemangioma and atherosclerosis [13,14]. Despite their distinct aetiologies, these disorders can
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be characterised as angiogenesis-dependent diseases [15] and are either caused or exacerbated by
an imbalance between the production/activity of anti- and pro-angiogenic factors [16]. Among the
pro-angiogenic endogenous molecules, vascular endothelial growth factor (VEGF) is a major regulator
of blood vessel formation in health and disease [1]. Initially, VEGF was termed vascular permeability
factor (VPF) due to its ability to increase the permeability of blood vessels [17,18]. Following subsequent
observations of the additional effects of VPF on endothelial cells and concomitant cloning, VPF was
renamed VEGF [19].
The VEGF family of proteins comprises VEGF-A, VEGF-B [20], VEGF-C, VEGF-D, Placental
Growth Factor (PlGF) [21], the virus-encoded VEGF-E and the snake venom-derived VEGF-F [22–24].
VEGF-A is the best characterised family member being the most potent stimulator of angiogenic
processes and therefore a target of numerous anti-cancer therapeutics [25]. VEGF-A is a large
anti-parallel homodimeric peptide that belongs to the “Cys-loop” superfamily of proteins, based on
a central knot motif of cysteine residues that form intramolecular disulphide bonds when assembled
into a folded structure [24,26]. VEGF-A is secreted by many cell types such as endothelial
cells [27,28], fibroblasts [29], smooth muscle cells [30], platelets [31], neutrophils [32], macrophages
and approximately 60% of all tumours [33]. VEGF-A secretion is also induced by ischemia and
inflammatory stimuli [34]. Cellular responses to VEGF-A are mainly driven by their binding to
their cognate receptor—the vascular endothelial growth factor receptors (VEGFRs). VEGFRs belong
to the class IV receptor tyrosine kinase (RTK) family [35] and show similarities to type III RTKs
platelet derived growth factor receptor (PDGFR), macrophage colony stimulating factor receptor
(M-CSFR), c-KIT and fms-like tyrosine kinase 3 (FLT3) [36]. There are three VEGFR subtypes which
are encoded by separate genes: VEGFR1 (Flt-1 in mice) and VEGFR2 (Flk-1; KDR) are structurally
similar, whereas VEGFR3 (Flt-4) has a proteolytically processed extracellular domain [37,38]. VEGFRs
are expressed by endothelial cells, macrophages, hematopoietic cells and smooth muscle cells [39–41].
Signalling of VEGF-A isoforms via VEGFR1 and VEGFR2 drive physiological and pathophysiological
angiogenesis, whereas lymphangiogenesis is mediated by VEGF-C/D isoforms via VEGFR3 [42].
Although VEGFR1 has a higher affinity for VEGF-A than VEGFR2, it shows decreased tyrosine kinase
activity and is therefore largely considered a decoy receptor that can negatively modulate VEGFR2
activity [43,44]. While VEGFR1 also plays a role in immune cell differentiation [45,46], VEGFR1 is
beyond the scope of this review (reviewed in [47]).
Alternative splicing of the Vegfa gene leads to different VEGF-A isoforms which have been
proposed to promote distinct signalling outcomes [16]. Through quantifying and comparing the
pharmacology of VEGF-A isoforms at VEGFR2, we can begin to comprehend how they differ
as distinct endogenous ligands. This could ultimately enable better understanding of molecular
mechanisms that give rise to distinct physiological outcomes with relevance in health and disease [16]
and future drug discovery efforts [25]. In this review, we have explored in detail the molecular
pharmacology of VEGF-A isoforms in terms of their receptor binding to VEGFR2 and downstream
signalling with particular reference to the influence of agonist efficacy and signalling coupling on
physiological outcomes.
2. Generation of VEGF-A Isoforms by Alternative Splicing
The regulation of vascular supply relies on tight regulation between factors that promote
(pro-angiogenic) or inhibit (anti-angiogenic) vessel development, via a mechanism that is reactive
to changes in oxygen and nutrient levels. VEGF-A transcription is affected by the local cellular
environment, such as during hypoxia [48,49] following secretion of growth factors, cytokines and
hormones, shear stress, genotoxic agents [50] and the activity of both oncogenes and tumour suppressor
genes [51]. The human Vegf a gene is located on chromosome 6p21.1 [52], with a coding region spanning
approximately 14 kilobases consisting of eight exons and seven introns. Alternative splicing of this
pre-mRNA selectively removes intron regions and joins specific combinations of exons to generate
distinct VEGF-A isoforms [53] (Figure 1). Alternative splicing is advantageous in expanding the
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repertoire of possible VEGF-A isoforms that can be produced from a single gene [54]. These isoforms
differ in respect to their length and are designated VEGFxxx, where xxx represents the number of
amino acids present in the final protein sequence. To date 16 distinct VEGFA isoforms have been
identified most commonly from six transcripts: VEGF111, VEGF121, VEGF145, VEGF165, VEGF189,
and VEGF206 [16,55,56]. An additional isoform, VEGF-Ax, was also identified in 2014 that arises from
programmed translational read-through (PTR) [56]. VEGF165a was the first isoform characterised
and remains the most extensively investigated in respect to its function, signalling, expression and
pathological roles [19]. As a potent stimulator of angiogenesis, VEGF165a is considered the prototypical
pro-angiogenic VEGF-A isoform. Altered VEGF-A isoform expression has been well documented in
tissues during physiological and/or pathological conditions [57–61].
Figure 1. Schematic illustrating the structure of vascular endothelial growth factor A (VEGF-A)
isoforms. The VEGF-A gene consists of eight exons, which can be alternatively spliced to generate
a range of VEGF-A isoforms. These isoforms differ in length and have been designated VEGFxxx,
where xxx represents the number of amino acids present. Each exon contains residues identified as
conferring distinct properties if included in the resultant isoform, including VEGFR2, extracellular
matrix (ECM) and Neuropilin (NRP) binding. A major site of alternative splicing occurs at exon
8, whereby proximal splicing results in the prototypical VEGFxxxa forms and distal splicing the
“anti-angiogenic” VEGFxxxb isoforms containing exon 8b. Additionally, post translational read-through
(PTR) using a non-canonical stop codon results in the VEGF-Ax isoform which contains a 22 amino acid
extension in its C terminal domain.
Boundaries between exons are defined by splicing sites which are recognised by a dynamic
complex of proteins located in the nucleus called the spliceosome [62], containing five small nuclear
ribonucleoproteins (snRNPs)—U1, U2, U4, U5 and U6—plus associated accessory proteins U2AF
and SF1. VEGF-A splicing is also regulated by a series of RNA binding proteins, most commonly
the serine/arginine (SR) proteins, chiefly SRSF1, SRSF2, SRSF5 and SRSF6 [54]. SR proteins are
phosphorylated in the cytoplasm at multiple serine/arginine and proline/serine repeats to enable their
subsequent translocation to the nucleus and allows a degree of spatial regulation of splicing. Once in
the nucleus, SR proteins typically bind to regulatory sites in VEGF-A pre-mRNA—exonic sequence
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enhancers [63,64]—which trigger exon removal. One such kinase responsible for phosphorylating SR
proteins is the constitutively active kinase SRPK1 [63]. Alterations in SRPK1 expression have been
identified (via both upregulation and downregulation) in a range of malignancies. This has led to
the development of SRPK1 inhibitors targeting aberrant angiogenesis through altering splicing of
endogenous VEGF-A isoforms [63,65,66].
The distinct exons included in each isoform confer different properties (Figures 1 and 2). Exons 1–5
are constitutive exons and are therefore present in all VEGF-A isoforms. These encode a signal
sequence (exons 1/2) that is cleaved in the processed form of VEGF, a glycosylation site (Asp74),
a potential plasmin cleavage site (Arg110 and Ala111) [67] and residues responsible for VEGFR1 and
VEGFR2 binding (Figure 2A,C) [16,68]. A major site of alternative splicing of the Vegf a gene centres
on exons 6 and 7. Residues in exons 6a and 7 interact with electronegative heparin sulphate in the
extracellular matrix, which has important implications for isoform bioavailability [69–71]. The shorter
isoforms VEGF111 and VEGF121 both lack exons 6 and 7, and as a consequence are not tethered to the
extracellular matrix (ECM) and are freely diffusible [70,72]. In contrast the longer isoforms VEGF145,
VEGF189 and VEGF206 containing both exons 6a and 7 can bind with high affinity to heparin sulphate
glycoproteins [73] (Figure 1). The prototypical VEGF165a is an intermediate between these freely
diffusible and bound isoforms, in that following secretion 50–70% remains cell or ECM bound [72].
A second major site of alternative splicing is driven by the choice of differential 3′ splice acceptor
sites within exon 8. In 2002, Bates et al. identified the VEGFxxxb family of isoforms [74]. These isoforms
arise due to distal splicing at a site located 66 base pairs downstream of the proximal splicing site,
resulting in isoforms that contain exon 8b (Figures 1 and 2) [51]. In respect to their sequences,
VEGFxxxa and VEGFxxxb isoforms only differ in the six amino acids found at their C termini; VEGFxxxa
isoforms end in the sequence CDKPRR, whereas VEGFxxxb isoforms terminate in SLTRKD [75].
Based on both in vitro and in vivo experimental evidence, VEGFxxxa isoforms are considered to be
“pro-angiogenic” as major mediators of vascular permeability, cell proliferation, survival and migration,
and angiogenesis [76]; in contrast, VEGFxxxb isoforms have been reported to have “anti-angiogenic”
properties [74,77,78], with evidence that these isoforms may act as regulators and inhibitors of
VEGFxxxa-induced pro-angiogenic activity [51,77]. Interestingly, in quiescent vessels, a higher
proportion of total VEGF-A is represented by VEGF165b, which is then downregulated in cancer where
a switch to pro-angiogenic isoform expression is observed to drive tumour angiogenesis [74,77,79].
Proximal or distal splicing of exon 8 can be influenced by external stimuli, as proximal splicing has
been promoted by insulin like growth factor (IGF1) or tumour necrosis factor alpha (TNFα), whereas
stimulation with tumour growth factor beta 1 (TGF-β1) has promoted distal splicing [51]. This bias
was governed by the specific SR protein splice factor that was bound to a sequence within exon 8a
(SRSF1) or 8b (SRSF6). It is worth noting that this bias may not be consistent in all cell types, however
this highlights how isoform expression can be context dependent. There has been some debate as to
the existence of VEGFxxxb isoforms physiologically [80,81], with genome wide RNA sequencing data
of the human transcriptome questioning whether the relevant exon-exon junctions in the Vegfa gene
are present [81].
VEGF-Ax, recently identified by Eswarappa et al. [56], is the result of extended translation
beyond the canonical stop codon of VEGF-A mRNA due to the presence of an alternative stop codon
within the 3′ untranslated region (Figures 1 and 2). PTR is at least partially regulated by the A2/B1
ribonucleoprotein acting as a trans regulatory factor. The resultant VEGF-Ax therefore contains a 22
amino acid extension encompassing both exons 8a encoded CDKPRR and exon 8b encoded SLTRKD
sequences [56,82]. The physiological role of VEGF-Ax is still yet to be fully elucidated with evidence it
exhibits both “anti” and “pro-angiogenic” signalling [56,82].
3. VEGF-A Ligand/Receptor Binding
VEGFR2 is a large 151 kDa membrane protein consisting of 7 extracellular immunoglobulin
(Ig)-like domains, a single transmembrane helix and a split intracellular kinase domain [83]. VEGF-A is
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an endogenous agonist for VEGFR2, binding the orthosteric ligand binding site across Ig-like domains
2 (D2) and D3 with a stoichiometry of one VEGF-A dimer across a VEGFR dimer [84,85]. X-ray and
NMR structures have identified binding interfaces between VEGF-A and its receptors, confirming key
exposed residues at each pole of the homodimer interacting with VEGFR1 [86–88] and VEGFR2 [84].
As each VEGF-A isoform contains residues encoded by exons 2–5 (Figure 1), residues interacting
with VEGFR1 and VEGFR2 are not removed by alternative splicing (Figure 2A,C). Every isoform
also contains cysteine residues that form intermolecular disulphide bonds such that all isoforms are
dimeric, as well as forming intramolecular disulphide bonds assembling the Cys-loop folded structure
(Figure 2A,C). In contrast, residues identified by structural studies that interact with co-receptor
Neuropilin-1 (NRP1) or components of the ECM are absent in some VEGF-A isoforms (Figure 2B,C).
The inability to crystallise both the N-terminal (exons 2–5) and C-terminal (exons 6–8) together suggest
flexibility between these N- and C-terminal regions of VEGF-A, however the current lack of structural
information on full-length VEGF-A isoforms has prevented understanding of the stoichiometry of
macromolecular complex assembly.
Figure 2. Molecular structure of VEGF-A. (A) Anti-parallel homodimeric structure of VEGF-A encoded
by exons 2–5 (PDB:1VPF), showing distinct VEGF monomers in grey and gold and residues interacting
with VEGF receptors shown in blue; (B) C-terminus of VEGF165a is encoded by exons 7–8a (PDB:4DEQ),
with residues that bind heparin (yellow) and Neuropilin-1 (green) highlighted; (C) Amino acid residues
present in exons of the human VEGF-A sequence that interact with known binding partners. The open
reading frame was derived from transcript NM_001025366.2 with exons denoted according to UniProt
(P15692) and residues numbered according to residues in the final VEGF-A peptide following cleavage
of the signal sequence. Based on published X-ray crystal structures, residues are highlighted that form
non-covalent interactions with VEGFR1 [88], VEGFR2 [84], Neuropilin-1 [89] or heparin [70]. Cysteine
residues forming intermolecular or intramolecular disulphide bonds, important for dimeric or folding
structure, respectively, are also highlighted [26].
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Ligand binding affinity is the strength of the interaction between a ligand and its receptor,
which can be quantified as the concentration of ligand required to bind 50% receptors at equilibrium
(equilibrium dissociation constant, Kd) [90]. Traditionally, VEGF-A binding has been investigated in
cells expressing VEGFR2 using radiolabelled [125I]-VEGF165a (Table 1), in which radioligand affinity
(Kd) was determined by quantifying bound ligand with saturating concentrations [91,92]. Competing
“hot” [125I]-VEGF165a with increasing concentrations of “cold” ligand allows the determination of
affinity of unlabelled VEGF-A isoforms [44,70,77,93] (Table 1). Biochemical techniques have also been
used to quantify VEGF-A binding affinities as a cell-free alternative using isolated receptors, including
surface plasmon resonance (SPR) [85], solid-phase enzyme-linked assays [56,94] and thermodynamic
calorimetry measurements [84,85]. Binding affinities determined using biochemical techniques using
truncated VEGFR2 yielded higher estimated binding affinities than those determined with radioligand
binding (Table 1), however radioligand binding experiments also have caveats beyond safety and
cost. Recently, bioluminescence resonance energy transfer (BRET) was developed as a proximity-based
technique using the novel luciferase NanoLuc to monitor ligand binding to GPCRs [95,96]. This allows
ligand/receptor interactions to be monitored in real-time to receptors expressed within their native
membrane environment. This has been applied to monitor RTK pharmacology, quantifying the binding
of single site fluorescently-labelled VEGF165a (Figure 3a) to full-length human VEGFR2 in living cells
at 37 ◦C [97].
Regardless of technique used, all VEGF-A isoforms, including those directly comparing
“pro-angiogenic” VEGF165a and “anti-angiogenic” VEGF165b [77,79,97], have been shown to bind
to VEGFR2 with nanomolar affinities (Table 1). Relatively lower affinities were seen for VEGF145a
and VEGF189a at VEGFR2 when compared to the prototypical VEGF165a, demonstrated by a higher
Kd values (Table 1). However, in terms of their pharmacology, these are small differences in affinity
(VEGF165a Kd 0.15 nM vs. 1.02–1.82 nM; Table 1), particularly as physiological VEGF-A concentrations
are estimated within the picomolar range [98]. As all VEGF-A isoforms contain residues that interact
with VEGFR2 (Figure 2A,C) and pharmacological binding studies suggest all VEGF-A isoforms bind
VEGFR2 with a similar nanomolar affinity (Table 1), this illustrates that VEGF-A/VEGFR2 binding
alone is insufficient to explain functional distinctions between isoforms in terms of their signalling
downstream of VEGFR2.
Table 1. Binding affinities of VEGF-A isoforms determined at VEGFR2.
Isoform Technique Expression System Binding Affinity * Ref.
VEGF165a
Radioligand
binding
Human kidney tissue in situ 0.01–0.04 nM [91]
HUVECs 0.17 nM [92]
Balb/c expressing VEGFR2 0.29 nM [92]
COS-1 cells expressing VEGFR2 0.34 nM [92]
PAE cells expressing VEGFR2 0.76 nM [44]
PAE cells expressing VEGFR2 0.097 nM [93]
SPR VEGFR2 ligand binding domains (D2/D3) 36.7 nM [85]
ITC
VEGFR2 ligand binding domains (D2/D3) 18 nM [85]
VEGFR2 ligand binding domains (D2/D3) 170 nM [84]
VEGFR2 extracellular domain (D1–D7) 2670 nM [84]
NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.15 nM [97]
VEGF165b NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.39 nM [97]
VEGF121a
ITC
VEGFR2 extracellular domain (D1–D7) 1120 nM [84]
VEGFR2 ligand binding domains (D2/D3) 93 nM [84]
NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.34 nM [97]
VEGF145a NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 1.82 nM [97]
VEGF189a NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 1.02 nM [97]
* Ligand binding affinity quantified as equilibrium dissociation constant of the “hot” ligand (Kd) or competing
ligand (Ki). Abbreviations: Bioluminescence resonance energy transfer (BRET) using NanoLuciferase (NanoBRET);
isothermal titration calorimetry (ITC); surface plasmon resonance (SPR).
Int. J. Mol. Sci. 2018, 19, 1264 7 of 27
Figure 3. Quantifying VEGF-A isoform binding and downstream nuclear factor of activated T-cells (NFAT)
signalling to derive pharmacological parameters. (A) Ligand binding affinities to VEGFR2 were quantified
using HEK293 cells stably transfected with the full-length human VEGFR2 tagged at its N-terminus with
the novel luciferase NanoLuc. Bioluminescence resonance energy transfer (BRET) experiments were then
performed, whereby the close proximity of the donor NanoLuc tag with bound VEGF165a fluorescently
with tetramethylrhodamine (VEGF165a-TMR) facilitates the non-radiative transfer of this energy to excite the
acceptor TMR fluorophore which itself emits light at a longer wavelength. Cells were co-stimulated using
a fixed concentration (3 nM) of single-site fluorescently labelled VEGF165a (VEGF165a-TMR) and increasing
concentrations of competing unlabelled VEGF-A isoforms (60 min at 37 ◦C). These data were normalised
to percentage displacement of VEGF165a-TMR alone and binding affinities (pKi values) of unlabelled
isoforms estimated using the Cheng–Prusoff equation with VEGF165a-TMR Kd values calculated from
previous saturation experiments (see [97] for more details). (B) Functional potencies of VEGF-A isoforms
were derived from an NFAT reporter gene assay, whereby a Firefly luciferase inserted downstream of the
NFAT promoter sequence was used to investigate the potency of unlabelled VEGF-A isoforms in respect to
stimulating downstream NFAT production. HEK293 cells stably expressing full-length human VEGFR2
were stimulated with a concentration response course of unlabelled VEGF-A isoforms (5 h at 37 ◦C/5% CO2).
A luminescence readout was indicative of NFAT production. All responses were expressed as a percentage
of 10 nM VEGF165a. The potency and efficacy of VEGF-A isoforms in respect to NFAT production were
calculated using non-linear least square regression. All data were pooled from 4/5 independent experiments
and expressed as± S.E.M. Figures modified from Kilpatrick et al. (2017) [97].
4. VEGFR2 Signalling
4.1. VEGFR2 Activation
VEGF-A isoforms have distinct signalling outcomes downstream of VEGFR2 activation [16]. Although
VEGF-A isoforms have similar binding properties at VEGFR2, activation of VEGFR2 is a complex multi-step
process. As well as VEGF-A binding its orthosteric ligand binding site, allosteric interactions can occur at
topographically distinct regions [99]. Allosteric homotypic interactions between VEGFR2 monomers at
Ig-like D4, D5 and D7 are an additional step necessary for VEGFR2 activation [84,100–103], as designed
ankyrin repeat protein inhibitors (DARPins) can sterically block these interactions and allosterically inhibit
VEGFR2 activation [103,104]. Ligand binding leads to a conformational twist throughout the extracellular
region of VEGFR2 reorienting distinct Ig-like domains, shown by electron microscopy [100], small angle
X-ray scattering [101], and the full-length crystal structure of structurally related VEGFR1 [88]. VEGF-A
binding consequently leads to the rotation of transmembrane helices [105–107], with similar configurations
induced by isoforms VEGF165a, VEGF165b and VEGF121a when measured using fluorescent resonance
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energy transfer (FRET) [107]. The intracellular region of VEGFR2 then undergoes conformational changes,
formed of N- and C-lobes [108] with ATP binding to the flexible N-lobe cleft which enables receptor
intrinsic kinase activity and phosphorylation of tyrosine residues in the C-lobe, notably Y1054 and
Y1059 in the activation loop, Y951 in the kinase insert domain and Y1175 and Y1214, respectively [109].
Tyrosine phosphorylation creates binding sites for the recruitment of cytoplasmic adaptor proteins
and initiates signalling pathways (reviewed in [37]). Signalling pathways downstream of VEGFR2
activation lead to numerous cellular fates (Figure 4). These include proliferation via PLCγ [110] and
ERK1/2 [111], focal adhesion kinase (FAK)-mediated cell migration [112] and cell survival through
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ protein kinase B (AKT) [113] (Figure 4). VEGFR2
signalling also leads to vascular permeability through FAK recruitment [114,115], p38 MAPK-mediated
actin cytoskeleton reorganisation [116] and eNOS activation [117,118]. These signalling pathways undergo
extensive cross-talk (reviewed in [42]). VEGFR2 is also dephosphorylated by protein phosphatase 1b (PTP1b)
localised to the endoplasmic reticulum [119,120] (Figure 4), highlighting the importance of spatiotemporal
trafficking on VEGFR2 activation.
Figure 4. VEGFR2 signal transduction and trafficking pathways mediated by VEGF-A. Schematic
representation of the signalling pathways elicited by the docking of adaptor proteins to major tyrosine
phosphorylation sites. Phosphorylation of Y951 residue leads to the recruitment of TSAd which in turns
binds and activates Src. Substrates for Src include molecules related to cell adhesion, vascular permeability,
and cell survival (via PI3K/AKT pathway activation). pY1175 mobilises SHB, which in turn activates FAK
(cell attachment and migration). SHB is also one of the Src substrates that are involved in the activation
of PI3K/AKT. Moreover, pY1175 residues recruit PLCγ, triggering Ca2+-dependent signalling, which in
turn results in transcriptional control of proliferation and cell migration. Cell motility is also regulated by
the recruitment of NCK to pY1214 leading to p38MAPK activation. VEGFR2 activation promotes its own
internalization with signalling continuing within endosomal compartments. After being internalized
to RAB5+ sorting endosomes, VEGFR2 can be recycled to the cell surface in RAB4+ (fast trafficking,
persistent intracellular signalling) or Rab11+ (slow trafficking, PTP1b-limited intracellular signalling)
endosomes. Alternatively, VEGFR2 undergoes lysosomal degradation in Rab7+ endosomes. PLCγ,
phospholipase Cγ; PIP2, phosphatidylinositol biphosphate; DAG, diacylglycerol; IP3, inositol trisphosphate;
PKC, protein kinase C; MAPK, mitogen-activated protein kinase; MEK, MAP/ERK kinase; ERK, extracellular
signal–regulated kinases; NFAT, nuclear factor of activated T-cells; TSAd, T cell-specific adaptor protein;
PI3K, phosphatidylinositol 3-kinases; PIP3, phosphatidylinositol triphosphate; BAD, Bcl-2-associated death
promoter; SHB, Src homology-2 domain containing protein B; FAK, focal adhesion kinase; PTP1b, protein
tyrosine phosphatase 1b. The dotted lines refer to signaling pathways that have additional elements to them
(e.g., other adaptor proteins/non direct signaling routes) that have not been included due to space. The solid
lines are for a direct signaling pathway. The blue arrows refer to the routes through which the receptor
trafficked for either recycling or degradation.
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4.2. Distinctions between VEGF-A Isoform Signalling
Functional comparisons of the extent to which VEGF-A isoforms can drive distinct VEGFR2 signalling
responses has largely come from phenotypic observations, such as changes in endothelial cell proliferation,
or relative levels of phosphorylated VEGFR2/downstream signalling proteins in endothelial cells using
Western blots. Despite the importance of VEGF-A concentration on both VEGFR2 binding and signalling
(Figure 4), quantifying physiological VEGF-A concentrations is problematic due to the need to consider
distinctions between circulating and extracellular VEGF-A, tissue-specific variation, as well as specific
VEGF-A isoform concentrations sequestered in the ECM (Section 5.2). Computational modelling of
systems pharmacology have predicted a relative expression of VEGF165 > VEGF189 > VEGF121 with total
tissue, extracellular or plasma VEGF concentrations below 30 pM [98]. Functional in vitro and in vivo
pharmacological experiments have typically quantified responses to agonist stimulation by the relative
maximal responses induced, which can give an indication of efficacy, as well as their potency, defined as the
concentration of ligand needed to produce an 50% activation/inhibition of the maximal effect (EC50/IC50)
inferred from concentration-response curves [90] (Figure 5). Pharmacological investigations of VEGF-A
signalling have largely been performed using fixed concentrations of ligand as opposed to full concentration
response courses, making it difficult to make direct comparisons of the relative activity of isoforms across
different signalling pathways and in different cellular backgrounds. This is due to the nature of agonism
requiring knowledge of both affinity and efficacy, as it is not just the affinity of a ligand for its cognate receptor
that governs the extent of the signalling response observed. Ligands of equal affinity can produce different
maximal responses in functional assays [121,122]. They can also produce different EC50 values if the maximal
responses are the same. This is due to the non-linear relationship that exists between receptor occupancy
(i.e., the proportion of receptors that are ligand bound) and the final functional responses observed in many
cells/tissues as a consequence of signal amplification [121,122]. High efficacy agonists can induce a maximum
functional response even at low levels of receptor occupancy (e.g., 20%). Here, a large degree of receptor
reserve is seen (i.e., EC50 is much lower the Kd), meaning a high percentage of receptors (e.g., 80%) are not
required to produce a maximal response. In contrast, a partial agonist cannot produce a maximal response
even when receptor occupancy is 100% where receptor reserve is non-existent (e.g., no “spare” receptors are
present). The extent of receptor reserve differs between agonists at the same receptor and between different
cell types due to changes in receptor expression level (Figure 5), different agonist efficacies, as well as the
coupling efficiency of receptors to signalling partners and the strength of signal amplification. As a result,
a ligand that is a partial agonist in a signalling pathway/tissue with low receptor expression (Figure 5B,C)
may exhibit full agonism when there is a higher degree of receptor reserve (Figure 5A). A single ligand may
therefore show “pluridimensional efficacy” in that it displays a range of efficacies depending on the level of
receptor expression, the cell background and signalling pathway observed [123].
As seen from estimations of binding affinity, all VEGF-A isoforms can bind to VEGFR2
with nanomolar affinity (Table 1, Figure 3a). However in vitro and in vivo observations have
suggested that stimulation with different VEGF-A isoforms can result in distinct phenotypic outcomes
(Figure 3B). Differences between isoforms can therefore not be attributable to affinity alone, but may
be explained by differences in their relative intrinsic efficacies and the impact of receptor expression
and signalling efficiency in different cells and tissues. The starkest of these phenotypic differences is
the classification of VEGF-A isoforms into “pro-angiogenic” VEGFxxxa or “anti-angiogenic” VEGFxxxb
groups. VEGF165a is the prototypical VEGF-A isoform that has been shown to act as a full agonist for
VEGFR2 driven signalling responses observed both in vivo and in vitro and is therefore typically used
as a reference ligand for investigating other VEGF-A isoforms [70,77–79,124–132]. Of the selective
isoforms studied, VEGF165a has been shown to induce the highest levels of phosphorylation of VEGFR2
(Y1175 residue), AKT and ERK [132].
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Figure 5. Comparison of full and partial agonists with different levels of receptor expression. (A) Agonist-
concentration response curve in a system with high receptor expression showing two agonists A and B,
which have the same dissociation constant (Kd), produce the same maximal response and appear as full
agonists. The curve for agonist A is shifted to the left (relative to agonist B) due to its higher efficacy than
agonist B and ability to produce a maximum response by only occupying a small fraction of the available
receptors. Agonist B has lower efficacy than agonist A and requires a higher concentration (equal to its Kd
value) to evoke 50% maximal response. In systems with medium receptor expression (B) or low receptor
expression (C), agonist B induces a lower maximal response than agonist A and can therefore be described
as a partial agonist. (D) When the system with low receptor expression is co-stimulated with a fixed
concentration of full agonist A and increasing concentrations of agonist B (green line), the partial agonist B
can effectively antagonize the response to agonist A. This is because receptors occupied initially by agonist
A are replaced with a lower efficacy agonist B that is only able to produce a small agonist response. The split
x axis shows both the response to the fixed concentration of agonist A only (left, blue bar) and increasing log
concentrations of agonist B.
Since its discovery in 2002 [74], the VEGF165b isoform has been characterised as “anti-angiogenic”
in relation to the prototypical VEGF165a. VEGF165b stimulation results in a reduced stimulation
of angiogenesis in vivo when compared to VEGF165a [77,79], as well as lower tumour vessel
density [133], endothelial cell proliferation [78,125,126,134], tubulogenesis and wound healing
in vitro [134]. These data are consistent with VEGF165b acting as a low efficacy agonist in some
signalling pathways rather than acting as an antagonist lacking any ability to activate VEGFR2
signalling. However, for responses in cells where VEGF165b is clearly acting as a weak partial
agonist it will be able to antagonise the agonist effect of more efficacious agonists (e.g., VEGF165a)
(Figure 5D). This is supported by biochemical observations that VEGF165b can induce phosphorylation
of VEGFR2, albeit to a decreased level when compared to the full agonist VEGF165a [125,128],
suggesting that VEGF165b can still partially activate VEGFR2. Additionally, VEGF165b can stimulate
the production of NFAT in HEK293 cells expressing VEGFR2 alone, with a comparable potency to
VEGF165a (EC50 VEGF165a 0.1 nM vs. VEGF165b 0.4 nM; Figure 3b) [97] albeit with decreased efficacy
in respect to VEGF165a (68.1% ± 5.7 of maximal VEGF165a response; Figure 3B) [97]. Co-stimulation
of VEGF165a with VEGF165b also leads to decreased maximal responses compared to VEGF165a alone
both in vivo and in endothelial cells indicative of VEGF165b partial agonism [77,79]. Phenotypically,
decreased vascular permeability has also been observed with VEGF165b treatment compared to
VEGF165a measured by both transendothelial electrical resistance and following macromolecules
conjugated to fluorescent FITC [128,129]. Cell-specific differences have been seen in respect to
VEGF165b induced phosphorylation of AKT in HMVECs [77] and HCAECs [134] where it is decreased
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when compared to VEGF165a, but is comparable to VEGF165a in HPMECs [128]. Additionally,
whilst differences in the extent of ERK phosphorylation were seen with VEGF165b vs. VEGF165a
in HPMECs [128] and PAECs (expressing VEGFR2) [126], the levels of pERK were indistinguishable
in HMVECs [77]. These differences in efficacy illustrate how the nature of VEGF-A agonism may
be heavily influenced by the expression level or localisation of VEGFR2, but also other VEGF-A
binding partners (VEGFR1, NRP1) or downstream adaptor proteins both in different physiological
and pathological cell systems [133].
For the shorter freely diffusible VEGF-A isoform, VEGF121a (Figure 1), evidence exists of it exhibiting
both partial and full agonism (in comparison to VEGF165a) depending on the signalling pathway observed.
In both in vivo angiogenesis [79,125] and in vitro measurements of signalling (Figure 3b), VEGF121a appears
to act as a partial agonist in comparison to VEGF165a. VEGF121a stimulation also leads to submaximal
HUVEC proliferation when compared to VEGF165a [124,126,130,132], with both a rightward shift in potency
and reduced maximal response also seen [67]. Compared to VEGF165a, VEGF121a also induced less
HUVEC motility and sprouting [124], as well as partial calcium signalling responses [97,131]. Western blots
performed by several independent groups have also suggested VEGF121a stimulation induces reduced
phosphorylation of VEGFR2 directly [20,124,130], as well as ERK [126] and PLCγ [131] when compared
to VEGF165a. In respect to NFAT production, VEGF121a showed comparable potency to VEGF165a
(0.3 vs. 0.1 nM respectively; Figure 3B) but reduced efficacy (65.9%± 8.8 of maximal VEGF165a response;
Figure 3b) [97]. However, evidence exists that the extent of VEGF121a agonism is pathway dependent,
for example, VEGF121a-induced ex vivo angiogenic sprouting has been shown as both comparable [70] and
lower [20] than VEGF165a, with similar trends also seen in respect to vascular permeability seen as both
comparable [132,135] and lower [136] than VEGF165a.
The ECM-bound isoforms, VEGF145a and VEGF189a, also show variations in the extent of agonism
at VEGFR2 depending on the signalling pathway observed. Relative to VEGF165a, VEGF145a is less able
to stimulate angiogenesis in vivo, albeit to a greater extent than observed with VEGF121a or VEGF165b
stimulation [125]. VEGF145a-induced HUVEC proliferation and permeability was also partial relative
to VEGF165a [132], however this same study also found VEGF145a-induced HUVEC migration was
comparable to VEGF165a [132]. Reduced VEGFR2 phosphorylation has been observed in both murine
endothelial cells [125] and HUVECs [132], as well as reduced ERK or AKT phosphorylation [132].
Although VEGF189a had similar functional activity to VEGF165a in terms of concentration-dependent
proliferation in HUVECs and migration of BAECs [127], autocrine expression in isolation revealed
distinctions in proliferation and cell survival [137]. Furthermore, in HEK293 cells lacking NRP1
expression and solely expressing VEGFR2, both VEGF145a and VEGF189a showed comparable potencies
to VEGF165a in respect to NFAT production (Figure 3b) albeit with decreased efficacy (71–72% of
maximal VEGF165a response; Figure 3b) [97].
Following its identification in 2014 [56], the novel isoform VEGF-Ax has also been characterised as
“anti-angiogenic” due to its functional similarities to VEGF165b. Based on the early in vitro and in vivo
evidence generated so far, VEGF-Ax has shown evidence of both full and partial agonism depending
on the signalling pathway investigated. VEGF-Ax induced a decreased maximum response relative
to VEGF165a in respect to VEGFR2 phosphorylation in HUVECs [56]. However, VEGF-Ax has also
been shown to induce vascular permeability and ex vivo migration of HUVECs as well as promote
BAEC proliferation to a comparable extent seen with VEGF165a stimulation [82]. VEGF-Ax possesses
functional similarities to the VEGFxxxb isoforms, although questions remain over how frequently
posttranslational read-through occurs to bypass the canonical stop codon and if this process occurs in
all cells equally.
5. Molecular Mechanisms Distinguishing between VEGF-A Isoforms
VEGFR2 is subject to complex regulation by numerous mechanisms that underlie context-
dependent signalling. It is therefore unsurprising that endogenous isoforms of varying lengths
or sequences have distinct signalling outcomes with implications for altered expression in health
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and disease [16]. The spatial and temporal regulation of both VEGFR2 in terms of trafficking,
and VEGF-A isoform bioavailability through ECM interactions, can influence isoform-specific
signalling. Endothelial cells also express interaction partners NRP1 [138] and integrins [139], as well
as other modulatory membrane and cytoplasmic proteins that may alter receptor expression or
localisation, ultimately influencing downstream signalling and phenotypic outcomes that distinguish
between VEGF-A isoforms.
5.1. Spatiotemporal Dynamics of VEGFR2 Trafficking
As demonstrated for other RTKs and G protein coupled receptors (reviewed in [140]), VEGFR2
undergoes endosomal signalling as it can signal from both the plasma membrane and intracellular
compartments [42,132,141]. Activation of ERK requires VEGFR2 endocytosis [141], however the
off-target effects of endocytic inhibitors on ERK activation requires careful interpretation [142]. VEGFR2
is localised at both the plasma membrane and in early endosomes due to constitutive VEGFR2
internalisation and recycling [143,144]. VEGFR2 can be internalised via clathrin-dependent [145,146]
and -independent mechanisms [147,148]. Following VEGF-A stimulation, ligand-receptor complexes
undergo internalisation within 15–20 min [97,149]. Ligand stimulation also triggers VEGFR2
recycling back to the plasma membrane [150], via short loop Rab4-positive endosomes or long loop
Rab11-positive endosomes [144] (Figure 4). Alternatively, ubiquitination can initiate proteolysis
and trafficking of VEGFR2 for lysosomal degradation [149,151] (Figure 4). The intracellular fate of
VEGFR2—recycling or degradation—regulates the duration, amplitude and specificity of the signalling
response [38,152], as the presence of activated VEGFR2 in early endosomes induces maximal ERK1/2
and AKT activation while p38 MAPK signal transduction is dependent on cell surface VEGFR2
expression [38]. Subcellular VEGFR2 trafficking is also important for receptor dephosphorylation due
to the intracellular localisation of the key regulator protein phosphatase 1b (PTP1b) [119,120]. Crucially,
some evidence has suggested isoform-specific trafficking of VEGFR2 [132,152], whereby VEGF165a
induces a greater degree of ubiquitinylation than the partial agonists VEGF121a or VEGF145a [132].
Additionally, VEGFR2 internalisation can be modulated by NRP1, a co-receptor that only selected
VEGF-A isoforms can interact with, rerouting VEGFR2 to long-loop recycling endosomes rather
than degradative pathways [153]. VEGFR2 trafficking can also be modulated by membrane proteins
VE-cadherin and ephrin B2 [145,154], however it is unknown whether these preferentially interact with
specific VEGF-A isoforms. Factors modulating the spatiotemporal dynamics of VEGFR2 trafficking
combined with evidence of endosomal signalling suggest a possible mechanism which may drive
VEGF-A isoform specific altered signalling.
5.2. Spatiotemporal Dynamics of VEGF-A Bioavailability
Regulation of the bioavailability of VEGF-A isoforms following secretion may contribute to
their differential biological and cellular responses [16,42]. VEGF-A isoform bioavailability is heavily
influenced by their differing abilities to interact with the ECM (Figure 1). Tethering to the ECM creates
localised concentrations of VEGF-A close to cells, which can be proteolytically released or cleaved
to generate shorter more diffusible isoforms, creating VEGF-A gradients that can amplify VEGF-A
signalling in times of angiogenic need [155]. Residues encoded by exon 6a, present in VEGF145,
VEGF189 and VEGF206 (Figure 1), as well as exon 7-encoded residues, can interact with electronegative
heparin through arginine residues confirmed by mutagenesis [70] and an NMR solution structure [156]
(Figure 2B,C). Despite lacking exon 6a-encoded residues, VEGF165a binds heparin with relatively high
affinity through exon 7-encoded arginine residues (Kd = 40–157 nM) [157] (Figure 2B,C). In addition
to its role in sequestering VEGF-A isoforms, heparin can potentiate binding of VEGF165a to VEGFR2,
but not freely diffusible VEGF121a as it lacks exon 6/7 [158–160]. Using SPR, Teran and Nugent
(2015) did not observe any binding of VEGFR2 itself to heparin, leading them to postulate that
VEGF165a bridges VEGFR2 and heparin so that they form a larger complex [160]. Functionally the
presence of heparin increases VEGF165a, but not VEGF121a, mediated phosphorylation of VEGFR2 and
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enhanced VEGF165a-induced HUVEC mitogenesis in a dose-dependent manner [161]. Heparin also
was shown to substantially enhance the affinity of interactions between VEGF165a and co-receptor
NRP1 [162,163], illustrating the interplay between these modulatory factors on VEGF-A bioavailability
and pharmacology.
5.3. Interactions with Co-Receptor Neuropilin-1 (NRP1)
VEGFR2 signalling is selectively enhanced by its co-receptor NRP1 [164,165], a multifaceted
single transmembrane glycoprotein with which only some VEGF-A isoforms can bind (Figure 2b,c).
NRP1 is also involved in neuronal guidance through binding structurally and functionally unrelated
class 3 semaphorins at a distinct extracellular domain [163,166], however its functional role in vessel
development is evident from the severe cardiovascular abnormalities exhibited in Nrp1 knockout
mice [167–169]. As with VEGFR2 [170], NRP1 upregulation in malignant tumours is correlated to
aggressive cancer phenotypes [170–172]. NRP1 selectively potentiates VEGFR2-mediated endothelial
cell motility and vascular permeability with minimal effect on proliferation, driving arterial vessel
development in vivo [173–175]. Molecular mechanisms enhancing VEGFR2 signalling were further
elucidated following the use of antibodies [124] or siRNA [20] that blocked NRP1 leading to reductions
in VEGF165a-induced VEGFR2 and ERK phosphorylation, respectively, in vitro. VEGF-A binds the b1
domain of NRP1 [89,162,176] at exposed Tyr297 and Asp320 residue sidechains [89,177,178], primarily
via an exon 8a-encoded arginine residue (CDKPRR; critical arginine underlined) with homologous
interacting residues in tuftsin (TKPR) [176,179] and peptide ATWLPRR [180,181]. VEGF165a has
a comparable binding affinity for NRP1 compared to VEGFR2 determined by radioligand binding
(Kd < 3 nM) [92,159], while cell-free SPR-derived Kd values were ~100-fold higher [124,182]. With no
direct VEGFR2/NRP1 binding interface identified, NRP1 is thought to modulate VEGFR2 through
forming a multimeric complex bridged by NRP-binding VEGF-A isoforms. These dimeric VEGF-A
ligands then interact with VEGFR2 and NRP1 via separate ends of the peptide [165,183] (Figure 2).
HUVECs express more NRP1 than VEGFR2, quantified as 35,000 NRP1 receptors compared to
6000 VEGFR2 receptors per cell [152]. While NRP1-mediated VEGFR2 modulation is typically thought
to arise from receptors expressed in the same cell, NRP1 expressed by adjacent cells can have distinct
effects on VEGFR2 signalling, adding another layer of complexity [184]. NRP1 has a 44-amino acid
intracellular domain which lacks catalytic activity, suggesting it may not be capable of signalling in its
own right. However, its short cytoplasmic tail does contain a Serine-Glutamate-Alanine motif that
interacts with PDZ domain-containing synectin [185–187]. NRP1 is suggested to modulate VEGFR2
trafficking or expression [153], likely via synectin-mediated myosin VI recruitment which is capable of
transporting internalised receptors along actin filaments towards the cell body [188–191]. Interestingly
VEGF-A isoforms show differences in respect to NRP binding. VEGF165b [79,126] and VEGF-Ax [56,82]
cannot bind NRP1, whereas VEGF165a [79,89,92,124–126,159,182,192] and VEGF189a [193] containing
exons 7- and 8a-encoded residues can bind NRP1. There are conflicting reports regarding whether
VEGF121a, the shorter VEGF-A isoform containing exon 8a-encoded CDKPRR but lacking exon 7,
can bind NRP1 (reviewed in [194]). While cell-free assays measured low affinity binding [89,124,126],
other assays have not detected any interaction between VEGF121a and NRP1 [79,82,125], suggesting
VEGF121a may be unable to bridge the multimeric NRP1/VEGFR2 complex. Interestingly despite
containing both exon 8a-encoded (CDKPRR) and the exon 8b-encoded (SLTRKD), VEGF-Ax is unable
to bind NRP1 [56,82], with suggestions that this may be due to the 22-amino acid extension present
in VEGF-Ax sterically blocking binding [82]. The ability for heparin to synergistically enhance
VEGF/VEGFR2/NRP1 complex formation [160] in conjunction with the differential abilities of VEGF-A
isoforms to interact with NRP1, adds another layer of complexity to the VEGF/VEGFR2 signalling axis.
5.4. Heterodimer Formation with VEGFR1
Another potential mechanism that further diversifies VEGF/VEGFR2 signalling outcomes,
is via the formation of heteroreceptor complexes between VEGFR2 and other VEGFR subtypes [195–199].
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VEGFR2 mediated endothelial cell proliferation is negatively regulated by membrane-bound VEGFR1
homodimers [195,200]. There is a substantial decrease in VEGFR1 vs. VEGFR2 expression on the
surface of endothelial cells [138], therefore VEGFR1 homodimers are likely to be relatively rare when
compared to VEGFR1/VEGFR2 heterodimers [196]. Computational simulations suggest 10–50% VEGFR2
monomers are likely to exist as preassembled VEGFR1/VEGFR2 heterodimers during basal conditions
with no increase upon ligand stimulation [196,201]. Enzyme-linked immunosorbent assays (ELISA) have
identified the presence of preassembled VEGFR1/VEGFR2 complexes in highly vascularised organs in
mice, including lung, kidney and liver [196]. These preassembled complexes have also been documented
in primary cell lines, including bovine [202], porcine [203] and murine [204] endothelial cells. The use
of a novel dimeric bivalent ligand (VEGF-E/PIGF-1) formed by a VEGF-E monomer (specific-ligand
for VEGFR2) and a PIGF-1 monomer (specific-ligand for VEGFR1), allowed the selective activation
of VEGFR1/VEGFR2 heterodimers [196]. Stimulation with VEGF-E/PIGF-1 ligand in HUVECs led
to VEGFR2 phosphorylation, but relatively weak ERK1/2 phosphorylation and intracellular calcium
mobilisation, compared to VEGF-A and VEGF-E alone. Additionally, VEGF-E/PIGF-1 stimulation
promoted endothelial cell migration, sustained in vitro tube formation and vasodilation, but failed to
mediate proliferation and endothelial factor production, suggesting that mediation of these processes
may be bias towards VEGFR2 homodimers [196]. Moreover, these VEGFR1/VEGFR2 complexes also
inhibited VEGF-A-induced prostacyclin release, and phosphorylation of VEGFR2 was greater in cells
lacking VEGFR1, suggesting VEGFR1 may negatively modulate VEGFR2 activity in endothelial cells [196].
VEGFR2/VEGFR3 heterodimers have also been identified using proximity ligation assays [197–199],
however, compared to VEGF-C, VEGF-A did not enhance VEGFR2/VEGFR3 heterodimer association [197].
The phosphorylation pattern for VEGFR3 homodimers and VEGFR2/3 heterodimers also showed
differences [197–199], suggesting specific tyrosine residues may be exclusive substrates for VEGFR3
homodimers [197] and that VEGFR2/VEGFR3 heterodimers may show distinct signalling transduction and
biological properties. Interestingly VEGF-A isoforms with higher affinity for heparin, such as VEGF145 and
VEGF189, further potentiated VEGFR2/VEGFR3 heterodimer association when compared to VEGF165a or
VEGF121a [198], providing evidence of isoform-specific heterodimer formation with functional consequences
on signalling outcomes.
6. Conclusions and Future Perspectives
VEGF-A isoforms are distinct endogenous agonists for VEGFR2 that give rise to different
functional outcomes despite similar binding properties at VEGFR2. Considering prototypical
VEGF165a as a full agonist which stimulates maximal responses, several groups have provided
evidence that other VEGF-A isoforms are partial agonists in stimulating a sub-maximal response
relative to VEGF165a, including VEGF165b, VEGF121a, VEGF145a and VEGF-Ax. In terms of their
molecular pharmacology, the potency and efficacy of signalling responses are both pathway- and
context-dependent and heavily influenced by receptor expression and signalling protein coupling
efficiency. Mechanisms distinguishing between VEGF-A isoforms, including ECM and NRP1
interactions, highlight the importance of considering VEGF-A/VEGFR2 signalling with spatiotemporal
resolution. Applying quantitative pharmacological techniques used extensively with other cell
surface receptor families, such as G protein coupled receptors, could further inform our molecular
understanding of the VEGF/VEGFR signalling axis. The use of new technologies such as CRISPR/Cas9
would allow quantitative pharmacological observations to be performed in different cellular contexts
at physiological expression levels. Endogenous VEGF-A isoform expression has been shown to be
dependent on the tissue, disease state and splicing factors present, however fundamental questions
remain concerning how these isoforms lead to nuances of signalling at a molecular level.
VEGF-A is critical in the development of a number of angiogenesis-dependent conditions, such as
endometriosis [205], diabetic nephropathy [206], retinopathy [10], neuropathy [207], pulmonary
fibrosis [61], neovascular eye diseases [208] and ischaemic heart disorders [209–211], as well as
numerous cancer types as angiogenesis is a common hallmark for tumour development [6,212,213].
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VEGF-A/VEGFR2-mediated signalling is targeted through neutralising circulating VEGF-A using
bevacizumab (Avastin), blocking its receptors with RTK inhibitors (RTKIs) or inhibiting downstream
signalling pathways [214–216]. Existing approaches lack isoform specificity, as the epitope of
bevacizumab binds the VEGFR-binding region of VEGF-A (Figures 1 and 2) that are present in
all isoforms [217,218]. Recently, SRPK1 inhibitors have been developed to modulate VEGF-A isoform
expression through favouring splicing towards partial agonist VEGF165b rather than full agonist
VEGF165a [63,65]. Crucially, approved therapeutics used in oncology largely lack long-term efficacy
due to the recurrent emergence of resistance mechanisms [219–221]. Anti-cancer therapeutics targeting
VEGF-A/VEGFR2 are often used in combination with chemotherapy [25]; as a genotoxic therapeutic
agent, chemotherapeutics may promote splicing to VEGF111 [50]. Numerous RTKIs also have on-target
adverse effects due to the scope of VEGFR signalling pathways, such as hypertension caused by
inhibiting pathways leading to vascular permeability [222] and vasoconstriction [223]. Molecular
pharmacology forms the basis of drug development, therefore further elucidating the mechanisms that
distinguish between VEGF-A isoform pharmacology and how these are orchestrated in health and in
disease is fundamental to developing novel ways of targeting VEGF/VEGF receptors.
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Abbreviations
BRET Bioluminescence Resonance Energy Transfer
eNOS Endothelial Nitric Oxide Synthase
ERK Extracellular Signal-Related Kinase
FAK Focal Adhesion Kinase
GPCR G Protein-Coupled Receptor
HEK Human Embryonic Kidney cells
HMVECs Human Microvascular Endothelial Cells
HPMECs Human Pulmonary Microvascular Endothelial Cells
HUVECs Human Umbilical Vein Endothelial Cells
MAPK Mitogen-Activated Protein Kinases
NFAT Nuclear Factor of Activated T-Cells
NRP1 Neuropilin-1
PAECs Porcine Aortic Endothelial cells
PI3K Phosphatidylinositol 3-Kinase
PLCγ Phospholipase Cγ
RTK Receptor Tyrosine Kinase
VEGF Vascular Endothelial Growth Factor
VEGFR Vascular Endothelial Growth Factor Receptor
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